<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467751</url>
  </required_header>
  <id_info>
    <org_study_id>167/10</org_study_id>
    <nct_id>NCT02467751</nct_id>
  </id_info>
  <brief_title>Women With Polycystic Ovary Syndrome (PCOS)</brief_title>
  <acronym>PCOS</acronym>
  <official_title>Metabolic Profile in Women of Different Body Composition With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irmandade da Santa Casa de Misericordia de Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Irmandade da Santa Casa de Misericordia de Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic profile in women of different body composition with polycystic ovary syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Will be performed case-control study with women with Polycystic Ovary Syndrome, according to
      the Rotterdam criteria and body mass index between 18 to 29.9. The control group will consist
      of women without Polycystic Ovary Syndrome, with a body mass index of 18 to 29.9 and no other
      comorbidities. In both groups collect anthropometric data such as age, weight, height, waist
      circumference and blood pressure. Exams will be requested: metabolic profile (total
      cholesterol (mg/dL) and fractions, triglycerides (mg/dL), blood count, liver function (U/L)
      and classical glycemic index (mg/dL); hormonal profile - insulin (uIU/ml), luteinizing
      hormone (IU/L), follicle stimulating hormone (IU/L), thyreostimulating hormone (uIU/ML),
      total and free testosterone (ng/ml), 17-hydroxyprogesterone (ng/ml), dehydroepiandrosterone
      (ng/ml), prolactin (ug/ml). Body composition (BMI) will be performed by absorption technique
      of two low energy beams emitted by X-ray - full body densitometry (DEXA). Expected result: To
      evaluate visceral fat and truncal of patients with diagnosis of Polycystic Ovary Syndrome
      without obesity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic profile</measure>
    <time_frame>12 months</time_frame>
    <description>total cholesterol (mg/dL) and fractions, triglycerides (mg/dL) will estimate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Classical glycemic index</measure>
    <time_frame>12 months</time_frame>
    <description>Classical glycemic index (mg/dL) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>12 months</time_frame>
    <description>Liver function (U/L) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>luteinizing hormone</measure>
    <time_frame>12 months</time_frame>
    <description>luteinizing hormone (IU/L) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal profile - insulin</measure>
    <time_frame>12 months</time_frame>
    <description>Hormonal profile - insulin (uIU/ml) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle stimulating hormone</measure>
    <time_frame>12 months</time_frame>
    <description>Follicle stimulating hormone (IU/L) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thyreostimulating hormone</measure>
    <time_frame>12 months</time_frame>
    <description>thyreostimulating hormone (uIU/ML) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and free testosterone</measure>
    <time_frame>12 months</time_frame>
    <description>Total and free testosterone (ng/ml) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>17-hydroxyprogesterone</measure>
    <time_frame>12 months</time_frame>
    <description>17-hydroxyprogesterone (ng/ml) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydroepiandrosterone</measure>
    <time_frame>12 months</time_frame>
    <description>Dehydroepiandrosterone (ng/ml) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolactin</measure>
    <time_frame>12 months</time_frame>
    <description>Prolactin (ug/ml) will estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEXA</measure>
    <time_frame>12 months</time_frame>
    <description>Body composition will measure by DEXA scan</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Will be performed case-control study with women with Polycystic Ovary Syndrome, according
        to the Rotterdam criteria and body mass index between 18 to 29.9. The control group will
        consist of women without Polycystic Ovary Syndrome, with a body mass index of 18 to 29.9
        and no other comorbidities.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Polycystic Ovary Syndrome , body mass index of 18 to 29.9, without contraceptive use.

        Exclusion Criteria:

          -  Hypothyroidism, hyperprolactinaemia (defined as serum prolactin levels greater than 25
             ng/mL)

          -  Cushing's syndrome

          -  Nonclassical congenital adrenal hyperplasia (defined as serum 17-hydroxyprogesterone
             levels greater than 1.2 and 5.2 ng/mL in the follicular and luteal phase,
             respectively) and current or previous (within the last three months) use of oral
             contraceptives and other hormonal

          -  Antidiabetic and antiobesity drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina Macruz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade Santa Casa de Misericordia Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolina F Macruz, doctor</last_name>
    <phone>+5511999141447</phone>
    <phone_ext>Brazil</phone_ext>
    <email>carolmacruz@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irmandade Santa Casa Sao Paulo</last_name>
    <phone>+551121767385</phone>
    <phone_ext>Brazil</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carolina Furtado Macruz</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01225001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Macruz</last_name>
      <phone>+5511999141447</phone>
      <email>carolmacruz@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Irmandade da Santa Casa de Misericordia de Sao Paulo</investigator_affiliation>
    <investigator_full_name>Carolina Furtado Macruz</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>When I have finished my recruitment and analysis of the results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

